Responses
Clinical/translational cancer immunotherapy
Original research
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
Compose a Response to This Article
Other responses
No responses have been published for this article.
